Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)

Glaukos (NYSE:GKOS) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise overview of recent r

Benzinga02:01

Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs

Seeking Alpha01:55

Glaukos Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 20% Citigroup $120 → $130 Maintains Buy 05/06/2024 15.39% Jefferies $84 → $125 Upgrades Hold →

Benzinga01:24

Lake Street Maintains Buy on Tandem Diabetes Care, Raises Price Target to $75

Lake Street analyst Brooks O'Neil maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $60 to $75.

BenzingaMay 22 23:40

Tandem Diabetes Care Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 7.76% Stifel $45 → $55 Maintains Buy 05/06/2024 7.76% Barclays $39 → $55 Maintains Overweight 0

BenzingaMay 22 19:20

Shockwave Medical Gains After HSR Waiting Period for Sale to J&J Expires

Seeking AlphaMay 22 04:46